We can’t show the full text here under this license. Use the link below to read it at the source.
Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data
Comparison of diabetes treatments and their link to risk of pneumonia and severe sepsis in real-world patients
AI simplified
Abstract
SGLT2 inhibitors are associated with a 25% reduction in the risk of pneumonia and severe sepsis in patients with type 2 diabetes.
- SGLT2 inhibitors are linked to a hazard ratio of 0.75 for both pneumonia and severe sepsis compared to DPP-4 inhibitors.
- GLP-1 receptor agonists show a reduction in incident pneumonia and severe sepsis with hazard ratios of 0.60 and 0.61, respectively, when compared to DPP-4 inhibitors.
- The findings suggest that both SGLT2 inhibitors and GLP-1 receptor agonists may provide protective benefits beyond glucose control for patients with type 2 diabetes.
AI simplified
Key numbers
0.75
SGLT2i Pneumonia Risk Reduction
Hazard Ratio comparing SGLT2i vs. DPP-4i
0.60
GLP-1 RA Pneumonia Risk Reduction
Hazard Ratio comparing GLP-1 RA vs. DPP-4i
0.75
SGLT2i Severe Sepsis Risk Reduction
Hazard Ratio comparing SGLT2i vs. DPP-4i